Research Topic: NMDA receptor antagonists

The collective lie in ketamine therapy: a call to realign clinical practice with neurobiology

This article argues that ketamine therapy is commonly misunderstood as a consciousness-expanding psychedelic when it actually works through a completely different biological mechanism. The real therapeutic benefit comes from the brain’s natural reorganization in the days after treatment, not from the altered states people experience during the session itself. The authors call for medical practitioners to stop emphasizing the dissociative experience and instead focus on helping patients build healthy thought patterns during the recovery period when the brain is most ready to form new connections.

Read More »

New and emerging pharmacologic treatments for MDD

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

Read More »
Scroll to Top